No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RLMD241220P2500
- 2.15
- -0.01-0.46%
15min DelayClose Dec 20 16:00 ET
2.15High2.15Low
2.15Open2.16Pre Close10 Volume1.25K Open Interest2.50Strike Price2.15KTurnover0.00%IV3.31%PremiumDec 20, 2024Expiry Date2.14Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.17Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Relmada Therapeutics Shifts Focus After Study Discontinuation
Relmada Therapeutics Exploring Sale After Lead Program Failure
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017
Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017